Seroatlas · Human Serome Atlas

CALY

Neuron-specific vesicular protein calcyon

Also known as: CALCYON, CALY_HUMAN, DRD1IP, NSG3

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q9NYX4
Gene: CALY
Ensembl: ENSG00000130643
Chromosome: 10
Canonical length: 217 aa
Protein class: FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins

OverviewNCBI Gene

The protein encoded by this gene is a type II single transmembrane protein. It is required for maximal stimulated calcium release after stimulation of purinergic or muscarinic but not beta-adrenergic receptors. The encoded protein interacts with D1 dopamine receptor and may interact with other DA receptor subtypes and/or GPCRs. [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

217 residues, UniProt reviewed canonical sequence.

>Q9NYX4|CALY
     1  MVKLGCSFSG KPGKDPGDQD GAAMDSVPLI SPLDISQLQP PLPDQVVIKT QTEYQLSSPD
    61  QQNFPDLEGQ RLNCSHPEEG RRLPTARMIA FAMALLGCVL IMYKAIWYDQ FTCPDGFLLR
   121  HKICTPLTLE MYYTEMDPER HRSILAAIGA YPLSRKHGTE TPAAWGDGYR AAKEERKGPT
   181  QAGAAAAATE PPGKPSAKAE KEAARKAAGS AAPPPAQ

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against CALY can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Cell surface
Secreted: No
Transmembrane segments: 1
Mean surface accessibility (rSASA): 0.66
Highest tissue expression: 305 nTPM

Expression across tissuesHPA

Tissue

hypothalamus: 305 nTPM
basal ganglia: 178 nTPM
pituitary gland: 156 nTPM
cerebral cortex: 136 nTPM
amygdala: 85 nTPM
hippocampal formation: 83 nTPM

Single-cell type

other brain neurons: 787 nCPM
gonadotrophs: 416 nCPM
brain inhibitory neurons: 304 nCPM
pancreatic islet cells: 257 nCPM
brain excitatory neurons: 206 nCPM
ependymal cells: 196 nCPM

Immune cell

memory CD8 T-cell: 0.1 nTPM
naive CD4 T-cell: 0.1 nTPM
basophil: 0 nTPM
classical monocyte: 0 nTPM
eosinophil: 0 nTPM
gdT-cell: 0 nTPM

Brain region

hypothalamus: 551 nTPM
midbrain: 198 nTPM
cerebral cortex: 196 nTPM
pons: 193 nTPM
thalamus: 161 nTPM
basal ganglia: 153 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.18
gnomAD pLI: 0.04
gnomAD missense Z: 1.26
DepMap mean gene effect: 0.13
DepMap dependency class: none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

clathrin light chain binding

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of CALY in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

CLTA

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads CALY as an antibody target. Whether an autoantibody or antibody against CALY could matter depends on whether native CALY is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

CALY is annotated at the cell surface, where native CALY is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label CALY as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...